Nice post Fouremm, summarized well. Aside from the financial benefits of a partnering deal, I think the resulting leadership toward ultimate goals will be critical, along with a recognizable big boy BP putting significant cash where their mouth is will be very helpful for interim pps appreciation. Hope that's the case anyway ...

I also believe the science rocks, with attractive patent life, plethora of potential indications, huge unmet need(s), and a very nice potential pipeline for decades of growth and development, if in the right hands. That is huge for a forward looking BP - not a one trick pony, but rather a portfolio with the "safe and effective" science foundation being slowly but surely studied and established. Just need to get it in those "right hands" ... which have done this before, previously. The retail world needs to witness this actually happening, in order to let go of past frustrations, ineptitudes, risks, and nightmares.

We really need that "giddy up" moment where BP jumps in with cash and leadership to show the retail world this epigenetics/apabetalone "thingy" is real, it's happening, and now is the time to jump on this thing ...